Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Income (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Net Income data on record, last reported at -$38.3 million in Q3 2025.

  • For Q3 2025, Net Income fell 45.09% year-over-year to -$38.3 million; the TTM value through Sep 2025 reached $40.4 million, up 138.26%, while the annual FY2024 figure was -$88.7 million, 15.38% up from the prior year.
  • Net Income reached -$38.3 million in Q3 2025 per STOK's latest filing, down from -$23.5 million in the prior quarter.
  • Across five years, Net Income topped out at $112.9 million in Q1 2025 and bottomed at -$38.3 million in Q3 2025.
  • Average Net Income over 4 years is -$16.3 million, with a median of -$25.7 million recorded in 2024.
  • The widest YoY moves for Net Income: up 527.99% in 2025, down 45.09% in 2025.
  • A 4-year view of Net Income shows it stood at -$25.7 million in 2022, then dropped by 5.07% to -$27.0 million in 2023, then surged by 60.42% to -$10.7 million in 2024, then crashed by 258.9% to -$38.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$38.3 million in Q3 2025, -$23.5 million in Q2 2025, and $112.9 million in Q1 2025.